AdaptHealth (NASDAQ:AHCO) Price Target Cut to $12.00 by Analysts at UBS Group

AdaptHealth (NASDAQ:AHCO) had its price objective reduced by investment analysts at UBS Group from $13.00 to $12.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group’s target price would suggest a potential upside of 22.32% from the company’s previous close.

A number of other equities research analysts also recently weighed in on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $13.00 target price on shares of AdaptHealth in a report on Monday, August 12th. Canaccord Genuity Group dropped their target price on shares of AdaptHealth from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Robert W. Baird reduced their price target on shares of AdaptHealth from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Wednesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, AdaptHealth presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.36.

AdaptHealth Trading Up 6.9 %

Shares of AdaptHealth stock traded up $0.63 during midday trading on Wednesday, reaching $9.81. The company had a trading volume of 1,147,807 shares, compared to its average volume of 1,061,739. The stock has a fifty day moving average price of $10.76 and a 200 day moving average price of $10.44. AdaptHealth has a fifty-two week low of $6.37 and a fifty-two week high of $11.90. The firm has a market cap of $1.32 billion, a PE ratio of -1.88, a P/E/G ratio of 1.63 and a beta of 1.11. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.15 and a quick ratio of 0.94.

AdaptHealth (NASDAQ:AHCO) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.02). AdaptHealth had a positive return on equity of 9.58% and a negative net margin of 21.20%. The firm had revenue of $805.90 million during the quarter, compared to analyst estimates of $809.32 million. During the same quarter last year, the firm posted $0.19 EPS. The firm’s revenue for the quarter was up .2% on a year-over-year basis. On average, equities analysts anticipate that AdaptHealth will post 0.87 earnings per share for the current year.

Insider Activity at AdaptHealth

In other news, Director David Solomon Williams III sold 4,000 shares of the stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $11.26, for a total value of $45,040.00. Following the completion of the sale, the director now directly owns 36,899 shares of the company’s stock, valued at $415,482.74. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other AdaptHealth news, Director David Solomon Williams III sold 4,000 shares of AdaptHealth stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $11.26, for a total transaction of $45,040.00. Following the transaction, the director now directly owns 36,899 shares of the company’s stock, valued at $415,482.74. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Shaw Rietkerk sold 25,000 shares of the stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $11.24, for a total transaction of $281,000.00. Following the completion of the sale, the chief operating officer now owns 212,611 shares of the company’s stock, valued at approximately $2,389,747.64. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.43% of the stock is owned by insiders.

Hedge Funds Weigh In On AdaptHealth

Several hedge funds have recently modified their holdings of the company. Boston Partners purchased a new stake in shares of AdaptHealth during the first quarter valued at approximately $693,000. Russell Investments Group Ltd. bought a new stake in shares of AdaptHealth during the 1st quarter worth $2,242,000. Hillsdale Investment Management Inc. purchased a new position in shares of AdaptHealth in the 1st quarter worth about $4,240,000. First Eagle Investment Management LLC grew its position in AdaptHealth by 18.2% during the first quarter. First Eagle Investment Management LLC now owns 594,951 shares of the company’s stock valued at $6,848,000 after buying an additional 91,772 shares during the period. Finally, Vanguard Group Inc. increased its holdings in AdaptHealth by 8.9% during the first quarter. Vanguard Group Inc. now owns 10,017,722 shares of the company’s stock worth $115,304,000 after buying an additional 818,241 shares during the last quarter. Institutional investors own 82.67% of the company’s stock.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.